logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Affinia Therapeutics secured $40 million in Series C financing, led by New Enterprise Associates, to advance AFTX-201 for BAG3 dilated cardiomyopathy.

Oct 07, 2025•2 months ago

Amount Raised

$40 Million

Round Type

series c

WalthamresearchBiotechnologyHealth Care

Investors

Perceptive AdvisorsMass General Brigham VenturesGv (Formerly Google Ventures)F PrimeAvidity PartnersAtlas VentureAlexandria Venture Investments, LlcEli Lilly & CompanyNew Enterprise Associates

Description

Affinia Therapeutics has closed a $40 million Series C financing led by New Enterprise Associates, with participation from Eli Lilly & Company and other existing investors. The funds will support IND submission and clinical activities for AFTX-201, targeting BAG3 dilated cardiomyopathy. Affinia aims to submit an Investigational New Drug application by Q4 2025 and start a Phase 1/2 trial in Q1 2026. The financing also enables further development within Affinia's gene therapy pipeline.

Company Information

Company

Affinia Therapeutics

Location

43 Foundry Ave

Waltham, Massachusetts, United States

About

Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models.

Related People

6 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech